Page last updated: 2024-12-06

nsc 361456

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

pyrazine-2-diazohydroxide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	72766
CHEMBL ID	2008749
SCHEMBL ID	671572
MeSH ID	M0146322

Synonyms (29)

Synonym
NCI60_003296
brn 0774915
nsc 361456
diazohydroxide
n-nitrosopyrazinamine
pyrazinamine, n-nitroso-
2-pyrazine diazohydroxide
pyrazine-2-diazohydroxide
pyrazine diazohydroxide
nsc361456
nsc-361456
103829-56-7
nsc-374153
(e)-hydroxy(pyrazin-2-yl)diazene
n-nitrosopyrazin-2-amine
n-pyrazin-2-ylnitrous amide
AKOS006273168
unii-m0610gt9kv
m0610gt9kv ,
SCHEMBL671572
CHEMBL2008749
AUWFXUHWMBMPTI-UHFFFAOYSA-N
2-[(e)-hydroxydiazenyl]pyrazine #
2-pyrazinamine, n-nitroso-
pyrazine, 2-diazohydroxide
DTXSID50869407
EN300-7331341
(e)-n-[(pyrazin-2-yl)imino]hydroxylamine
PD159749

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Human BFU-e were greatly inhibited by PZDH, whereas murine BFU-e were relatively resistant to its toxic effects."	( Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Du, DL; Grieshaber, CK; Murphy, MJ; Volpe, DA, 1991)	0.28

Pharmacokinetics

Excerpt	Reference	Relevance
" Plasma elimination was fit to one (12/16) or two (4/16) compartment model with a mean k10 half-life of 11."	( Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. Ames, MM; Dhodapkar, MV; Reid, JM; Richardson, RL, 1994)	0.29
" Pharmacokinetic evaluations were performed on 28 of the 31 patients using an analytical method including derivatization of the parent drug to 2-chloropyrazine."	( Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Berezin, F; Janisch, L; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 1994)	0.51
" Pharmacodynamic analysis revealed no significant correlation between plasma levels at 5, 60, and 120 min; WBCs; absolute neutrophil and platelet count nadirs; and initial serum chloride or blood pH levels."	( Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Ansari, RH; Brockstein, BE; Garcia, JC; Mani, S; Meyer, SC; Mick, R; Ratain, MJ; Rhinehart, SN; Schilsky, RL; Stadler, WM; Taber, D; Vogelzang, NJ; Vokes, EE, 1998)	0.54

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (28.57)	18.7374
1990's	8 (57.14)	18.2507
2000's	1 (7.14)	29.6817
2010's	1 (7.14)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (42.86%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (57.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pyrimethamine Maloprim: contains above 2 cpds	1.97	1	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	2.08	1	0	nitrosamine	geroprotector; mutagen
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	6.94	14	6	diazine; pyrazines	Daphnia magna metabolite
nitrosomethylurethane Nitrosomethylurethane: An alkylating carcinogen that produces gastrointestinal and probably lung and nervous system tumors.	2.08	1	0	carboxylic ester
alkenes [no description available]	1.97	1	0
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	1.97	1	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
4-ipomeanol 4-ipomeanol: lung-toxic furanoterpenoid produced in moldy sweet potatoes in response to fungus infection; RN given refers to cpd without isomeric designation; structure	1.97	1	0	aromatic ketone
methyl(acetoxymethyl)nitrosamine methyl(acetoxymethyl)nitrosamine: RN given refers to parent cpd; structure in seventh source	2.08	1	0
nsc 338720 penclomedine: structure given in first source	1.97	1	0
hepsulfam hepsulfam: structure given in first source	2.38	2	0
3-azidopyrimethamine 3-azidopyrimethamine: structure given in first source; RN given refers to parent cpd	1.97	1	0
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	1.97	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
fostriecin fostriecin: compound contains a conjugated triene and an unsaturated lactone; from Streptomyces pulveraceus; structure given in second source. fostriecin : A structurally unique, naturally-occurring phosphate monoester isolated from the soil bacterium Streptomyces pulveraceus. It inhibits DNA topoisomerase II as well as several protein phosphatase including PP2A and PPA4, and exhibits potent antitumor activity against several cancer cell lines.	1.97	1	0	2-pyranones; olefinic compound; phosphate monoester; polyketide; primary allylic alcohol; secondary allylic alcohol; triol	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; topoisomerase II inhibitor

Condition	Relationship Strength	Studies	Trials
Cholera Infantum [description not available]	3.37	1	1
Blood Diseases [description not available]	3.37	1	1
Benign Neoplasms [description not available]	4.33	2	2
Hematologic Diseases Disorders of the blood and blood forming tissues.	3.37	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.33	2	2
Leukocytopenia [description not available]	3.37	1	1
Thrombopenia [description not available]	3.37	1	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.37	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.37	1	1
Cancer of Kidney [description not available]	3.38	1	1
Cancer of Liver [description not available]	3.38	1	1
Colorectal Cancer [description not available]	8.38	1	1
Invasiveness, Neoplasm [description not available]	3.38	1	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	3.38	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	3.38	1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.38	1	1
Cancer of Prostate [description not available]	3.38	1	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	3.38	1	1
Malignant Melanoma [description not available]	3.39	1	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	3.39	1	1
Leukemia L 1210 [description not available]	1.97	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	1.97	1	0
Cancer of Lung [description not available]	1.97	1	0
B16 Melanoma [description not available]	1.97	1	0
Experimental Neoplasms [description not available]	2.37	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	1.97	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	1.97	1	0

chemdatabank.com